MADISON, Wis.-BellBrook Labs, a provider of high-throughput screening tools for the drug discovery industry, announced that Invitrogen is adopting BellBrook's Transcreener HTS Assay Platform as part of a technology licensing agreement. Introduced in 2005, Transcreener HTS Assay Platform enables incorporation of hundreds of new drug targets into high-throughput screening.

 "We have received a tremendous response from the HTS commmunity since we introduced the concept of ADP immunodetection as a kinase assay method almost two years ago," says Bob Lowery, CEO of BellBrook Labs. "We've achieved enough traction in the market that now is the right time to increase penetration through outlicensing, and Invitrogen has a very strong presence."